Droplet Biosciences slashes cancer test time from 10 days to 2 using NVIDIA AI infrastructure

Droplet Biosciences Accelerates Residual Cancer Detection with NVIDIA | Newswise

Droplet reduc es genomic analysis time using NVIDIA Parabricks, enabling rapid turnaround of test results Newswise -- CAMBRIDGE, Mass., March 3, 2026 -- Droplet Biosciences, a diagnostics company pioneering lymph-based liquid biopsy testing, today announced that it is dramatically reducing genomic analysis time with NVIDIA AI infrastructure -- improving test turnaround times and enabling more timely, informed patient care. Droplet's LymphDetect™ test uses deep sequencing to interrogate the presence of residual cancer after a tumor has been removed. This requires tremendous computational power and, even with today's extensive cloud infrastructure, can take days to return a result. A new case study published today highlights the use of NVIDIA Parabricks, a GPU-accelerated software suite designed to drastically speed up genomic data analysis for DNA sequencing. Using Parabricks, Droplet has achieved an order-of-magnitude reduction in the analysis time required across critical bioinformatics steps. These performance gains will transform how quickly clinicians can receive actionable insights following cancer surgery. From Days to Hours: Accelerating Genomic Analysis Droplet focuses on detecting residual cancer after tumor removal by analyzing lymphatic fluid collected just 24 hours after surgery allowing clinicians to assess residual disease far earlier than other blood-based testing options. By moving from CPU-only pipelines to GPU-accelerated workflows, the Droplet reduced key analysis steps from days to hours with NVIDIA Parabricks, including: * Variant calling accelerated from up to 36 hours to under three hours * Sequence Alignment reduced from approximately ten hours to under one hour * Overall analysis timelines compressed from ten days to two days These gains are driven by NVIDIA's accelerated computing architecture, including the NVIDIA L4 Tensor Core GPU and NVIDIA L40S, which enable massive parallelization for genomics workloads. Faster Turnaround Means Better Patient Care "By leveraging NVIDIA Parabricks' acceleration, we've been able to compress some of our most computationally intensive steps from more than a day down to just a few hours," said Droplet CSO Wendy Winckler, PhD. "That speed matters. It means clinicians can get critical information sooner, make decisions at a more impactful moment, and ultimately deliver better, more personalized care for patients." In addition to performance gains, Droplet Biosciences has realized operational benefits. Despite higher hourly costs for GPU compute, the dramatically reduced runtime results in a lower overall cost per sample, reinforcing the scalability of GPU-accelerated genomics in a clinical setting. "We're very proud of our informatics team, led by Zhuosheng Gu, for continuing to advance our data processing capabilities," noted Droplet's CEO Greg Gosch. "We serve a unique segment of the cancer detection market where speed-to-result is particularly important for treatment decisions. We look forward to continuing our collaboration with NVIDIA to optimize and implement Parabricks technology into our cancer testing pipeline." The company is actively implementing additional acceleration tools with the goal of consistently analyzing results in as little as one day. About Droplet Biosciences, Inc. Droplet Biosciences, Inc., founded by leading oncology clinicians and clinical diagnostics experts, is based on the discovery that lymphatic fluid, derived from surgical drain fluid, has a high concentration of many valuable biomarkers. Droplet Biosciences built a strong IP portfolio on use of this unique and readily available biofluid and is building a platform for testing ctDNA presence across multiple cancers to guide adjuvant therapy decisions immediately after surgery. For more information, visit dropletbiosci.com.

Diagnostics startup Droplet Biosciences partners with Nvidia to speed cancer test results

Droplet Biosciences is partnering with Nvidia. They will use Nvidia's AI technology to speed up cancer test results after surgery. This collaboration aims to analyze genomic data much faster. The new method can detect residual disease in 24 hours. This is a significant improvement over current methods. Faster results mean patients can receive crucial information sooner. Diagnostics firm Droplet Biosciences said on Tuesday it is collaborating with Nvidia to use the chipmaker's AI infrastructure to speed up post-surgery cancer test results. The company has been using Nvidia Parabricks, a GPU-accelerated software suite, to drastically speed up genomic data analysis for ⁠DNA sequencing. ⁠Droplet said its method can detect residual disease in 24 hours by analyzing lymphatic fluid collected post surgery, compared to the four to six weeks it typically takes for tumor remnants to appear in blood-based tests. "By leveraging NVIDIA Parabricks' acceleration, we've been able to compress some of our ⁠most computationally intensive steps from more than a day down to just a few hours," said Droplet's chief ⁠scientific officer, Wendy Winckler. The company said it also realized operational benefits despite higher hourly costs for GPU compute, adding, "The dramatically reduced runtime results in a lower overall cost per sample." Faster turnaround allows patients to get the results while still in the hospital, while avoiding extra visits or long waits for traditional blood tests, it added. "We are using Parabricks to speed up our genomic analysis and shorten turnaround time from 10 days ⁠to less than five days," said Zhuosheng Gu, senior director of informatics, R&D at Droplet Biosciences. The diagnostic startup's first clinical test is for HPV-negative head and neck cancer, validated under the Clinical Laboratory Improvement Amendments. Droplet is a member of NVIDIA Inception, an AI startup accelerator program, and an NVIDIA AI Enterprise customer.